Posts

Nuvalent's cancer drug under FDA review, weeks after GSK closes $10.6B buyout

on

How GSK's new CEO lined up a major buyout to start his time at the top

on

GSK to Acquire Nuvalent for $10.6 Billion, Marking Its Largest Oncology Push in a Decade

on

GSK acquires lung‑cancer specialist Nuvalent for $10.6 billion

on

GSK to Acquire Nuvalent and Its Two Cancer Drugs Under FDA Review for $10.6 Billion

on

Nuvalent Shares Positive Phase 1/2 ALK Inhibitor Data Rivaling Pfizer’s Lorbrena in Lung Cancer

on

Nuvalent Reports Positive Pivotal Data for ROS1-Targeted Lung Cancer Drug; Rolling FDA Submission Planned

on